Soligenix, Inc. (SNGX) |
|
0.56 -0.015 (-2.61%)
|
12-02 15:59 |
|
Open: |
0.55 |
Pre. Close: |
0.575 |
|
High:
|
0.5816 |
Low:
|
0.55 |
|
Volume:
|
98,469 |
Market Cap:
|
24(M) |
|
|
|
Technical analysis |
as of: 2022-12-02 4:26:14 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 0.77 One year: 0.85 |
| Support: |
Support1: 0.55 Support2: 0.45 |
| Resistance: |
Resistance1: 0.66 Resistance2: 0.73 |
| Pivot: |
0.61 |
| Moving Average: |
MA(5): 0.56 MA(20): 0.62
MA(100): 0.69 MA(250): 0.65 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 8.5 %D(3): 9 |
| RSI: |
RSI(14): 36.5 |
| 52-week: |
High: 1 Low: 0.37 |
| Average Vol(K): |
3-Month: 76 (K) 10-Days: 50 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SNGX ] has closed above bottom band by 23.1%. Bollinger Bands are 0.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.58 - 0.59 |
0.59 - 0.59 |
|
Low:
|
0.54 - 0.55 |
0.55 - 0.55 |
|
Close:
|
0.55 - 0.56 |
0.56 - 0.57 |
|
Company Description |
|
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. |
Headline News |
Wed, 16 Nov 2022
Soligenix, Inc. to Showcase 2022 Milestones in Business Update Fireside Chat With PCG Advisory - Yahoo Finance
Mon, 14 Nov 2022
SNGX: HyBryte™ NDA to be Submitted Before the End of 2022… - Yahoo Finance
Sat, 12 Nov 2022
2022-11-11 | NDAQ:SNGX | Press Release | Soligenix Inc. - Stockhouse
Thu, 10 Nov 2022
Soligenix Announces Recent Accomplishments And Third Quarter 2022 Financial Results - Marketscreener.com
Mon, 07 Nov 2022
New to The Street Announces Five Corporate Interviews on Episode #404, Airing on the Fox Business Network, Tonight, Monday, November 7, 2022, at 10:30 PM PT - Yahoo Finance
Fri, 28 Oct 2022
SNGX: Invited to Submit BARDA Contract Proposal for Filovirus Vaccines… - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
43 (M) |
|
% Held by Insiders
|
4.295e+007 (%) |
|
% Held by Institutions
|
0.3 (%) |
|
Shares Short
|
361 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.519e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
771.9 |
|
Return on Equity (ttm)
|
-39.9 |
|
Qtrly Rev. Growth
|
858500 |
|
Gross Profit (p.s.)
|
4.07 |
|
Sales Per Share
|
-96.67 |
|
EBITDA (p.s.)
|
60910.8 |
|
Qtrly Earnings Growth
|
-0.4 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-12 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-2.1 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
329120 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2016-10-06 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
